{"filing":{"accession_number":"0001690585-26-000029","cik":"0001690585","ticker":"DNTH","company_name":"Dianthus Therapeutics, Inc. /DE/","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"dnth-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-20260612.htm"},"events":[{"id":10409,"run_id":9131,"accession_number":"0001690585-26-000029","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The company disclosed interim responder analysis data from a Phase 3 clinical trial (CAPTIVATE) for claseprubart in CIDP via an updated corporate presentation posted to its investor relations website. While clinical trial data updates can be material to investors evaluating the company's pipeline and regulatory prospects, this disclosure does not fit neatly into the more specific event categories (e.g., it is not a formal earnings release, M\u0026A activity, or executive change). The interim nature and presentation format suggest this is a material clinical milestone, warranting classification as other_material rather than forcing it into an ill-fitting category.","company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6716,"accession_number":"0001690585-26-000029","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The company disclosed interim responder analysis data from a Phase 3 clinical trial (CAPTIVATE) for claseprubart in CIDP via an updated corporate presentation posted to its investor relations website. While clinical trial data updates can be material to investors evaluating the company's pipeline and regulatory prospects, this disclosure does not fit neatly into the more specific event categories (e.g., it is not a formal earnings release, M\u0026A activity, or executive change). The interim nature and presentation format suggest this is a material clinical milestone, warranting classification as other_material rather than forcing it into an ill-fitting category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:19:29.550485+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6716,"accession_number":"0001690585-26-000029","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The company disclosed interim responder analysis data from a Phase 3 clinical trial (CAPTIVATE) for claseprubart in CIDP via an updated corporate presentation posted to its investor relations website. While clinical trial data updates can be material to investors evaluating the company's pipeline and regulatory prospects, this disclosure does not fit neatly into the more specific event categories (e.g., it is not a formal earnings release, M\u0026A activity, or executive change). The interim nature and presentation format suggest this is a material clinical milestone, warranting classification as other_material rather than forcing it into an ill-fitting category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:19:29.550485+00:00","company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","filing_date":"2026-06-12"}]}